（来源：泰林生物） 12月8-10日，为期三天的2025第二届高品质制水与高质量供水发展论坛在济南顺利举办。论坛邀请哈尔滨工业大学、同济大学、清华大学、中国科学院生 态环境研究中心、 北控水务集团、深圳环境水务集团、上海城投水务(集团)有限公司等就高品质制水、供水、水消毒、水安全监测、检测等进行案例分 享。 泰林作为水生态（微生物、寄生虫和浮游生物）检测整体解决方案提供商，携手合作伙伴江苏宏众百德生物科技有限公司，以"加速推进智慧化水质监 测"的理念，凭借"高效监测"的核心优势，应邀参加此次论坛。 展出产品包括藻类/两虫智能分析仪、藻类人工智能分析仪、全自动两虫检测系统、程控定量封口机、酶底物法微生物自动计数仪、微生物检验仪、酶底 物法微生物检测试剂、菌落总数检测组件、取样瓶和定量盘等系列设备和耗材，与行业专家、终端用户和参展企业一起交流分享准确、高效、智能的水质 检测与分析技术。 凌经理深入剖析了智能监测技术在饮用水安全保障中的核心价值，全面介绍了泰林创新构建的水生态检测产品体系及其在全场景下的应用实践。他指出， 泰林通过打造涵盖"在线监测、便携检测、应急响应"的立体化产品矩阵，成功构建了覆盖水源预警、过程 ...

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures in the life sciences sector [2] - The company provides high-quality products and solutions for industries such as biomedicine, healthcare, food and beverage, and environmental protection [2] Financial Performance - For Q1 2025, the company reported revenue of 66.94 million yuan, a year-on-year decrease of 16.33% [2] - The net profit for the same period was 3.53 million yuan, down 39.93% year-on-year, with a sales gross margin of 49.27% [2] Market Position - As of July 22, the company's stock closed at 22.8 yuan, with a rolling price-to-earnings (PE) ratio of 258.12, marking a new low in 163 days [1] - The average PE ratio in the medical device industry is 53.47, with a median of 37.00, placing Tailin Biological at the 117th position in the industry ranking [1][3] Shareholding Structure - As of Q1 2025, there is one institutional holder of Tailin Biological, which is a fund holding 511,200 shares valued at 1.1 million yuan [1]

Group 1 - The core viewpoint of the news highlights that TaiLin Bio's stock price closed at 19.04 yuan, down 2.91%, with a rolling PE ratio of 215.55 times, and a total market value of 2.308 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 48.08 times, with a median of 36.05 times, placing TaiLin Bio at the 117th position in the industry ranking [1][3] - The net inflow of main funds for TaiLin Bio on June 19 was 79,200 yuan, but over the past five days, there was a total outflow of 8.7005 million yuan [1] Group 2 - TaiLin Bio specializes in the research, production, and promotion of products related to microbiological testing and pollution control in the life sciences sector, providing high-quality solutions for various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a sales gross margin of 49.27% [2]

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, and process analysis, providing high-quality products and solutions for the biopharmaceutical, healthcare, food and beverage, and environmental protection industries [2] Financial Performance - For Q1 2025, the company reported revenue of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a gross profit margin of 49.27% [2] Market Position - As of May 19, the company's stock closed at 19.1 yuan, up 3.52%, with a rolling PE ratio of 216.23, marking a new low in 29 days. The total market capitalization is 2.315 billion yuan [1] - The average PE ratio in the medical device industry is 49.26, with a median of 36.71, placing Tailin Biological at the 117th position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders is 11,553, a decrease of 294 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]